Challenging the EAU Guidelines on Non-Muscle-Invasive Bladder Cancer (NMIBC): Single Instillation of Chemotherapy After Transurethral Resection of NMIBC and Chemotherapy Versus Bacillus Calmette-Guérin in Treatment of Intermediate-Risk Tumours

European Urology, Supplements

Volumn 9, Issue 3, 2010, Pages 406-410

  Brausi, Maurizio A ^a  

^a AUSL Modena   (Italy)

Author keywords

Bacillus Calmette Gu rin; EAU guidelines; Intravesical chemotherapy; Non muscle invasive bladder cancer; Transurethral resection of the bladder tumour; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; EPIRUBICIN; ISONIAZID; MITOMYCIN C;

BLADDER CANCER; BLADDER PERFORATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; CYSTOSCOPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INSTILLATION; GOLD STANDARD; HIGH RISK PATIENT; HUMAN; MEDICAL LITERATURE; NONMUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PEER REVIEW; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SINGLE DRUG DOSE; TRANSURETHRAL RESECTION; TREATMENT DURATION;

EID: 77950519956     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2010.02.002     Document Type: Review

References (23)

1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou J. Guidelines on TaT1 (non-muscle invasive) bladder cancer. European Association of Urology Web site. http://www.uroweb.org/professional-resources/guidelines/online.
2. Oosterlinck W., Solsona E., Akaza H., et al. Low-grade Ta (noninvasive) urothelial carcinoma of the bladder. Urology 66 Suppl 1 (2005) 75-89
3. Nieder A.M., Brausi M., Lamm D., et al. Management of stage T1 tumours of the bladder: international consensus panel. Urology 66 Suppl 1 (2005) 108-125
4. Sylvester R.J., van der Meijden A.P., Witjes J.A., et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66 Suppl 1 (2005) 90-107
5. Bladder Cancer Clinical Guideline Update Panel. Guidelines for the management of nonmuscle invasive bladder cancer (stages Ta,T1, and Tis): 2007 update. American Urological Association Web site. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bc.
6. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: bladder cancer including upper tract tumors and urothelial carcinoma of the prostate. NCCN Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
7. Herr H.W. High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumour. Semin Urol Oncol 15 (1997) 142-146
8. Sylvester R.J., Oosterlinck W., and van der Meijden A.P. A single immediate post-operative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190
9. Brausi M. Approaches to the management of non-muscle invasive bladder cancer: a review of current guidelines and best practice recommendations from the International Bladder Cancer Group. Eur Urol Suppl 7 (2008) 615-617
10. Dobruch J., and Herr H. Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?. BJU Int 104 (2009) 170-174
11. Kaasinen E., Rintala E., Hellström P., et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42 (2002) 167-174
12. Oddens J.R., van der Meijden A.P.M., and Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?. Eur Urol 46 (2004) 336-338
13. Zincke H., Utz D.C., Taylor W.F., Myers R.P., and Leary F.J. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol 129 (1983) 505-509
14. Cai T., Nesi G., Tinacci G., et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guérin efficacy in patients with non-muscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol 180 (2008) 110-115
15. Berrum-Svennung I., Granfors T., Jahnson S., Boman H., and Holmäng S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 179 (2008) 101-106
16. Solsona E., Iborra I., Ricos J.V., Monros J.L., Casanova J., and Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low-risk superficial bladder cancer: short and long-term follow-up. J Urol 161 (1999) 1120-1123
17. Gudjónsson S., Adell L., Merdasa F., et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55 (2009) 773-780
18. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
19. Böhle A., and Bock P.R. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology 63 (2004) 682-686
20. Malmström P.U., Sylvester R.J., Crawford D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56 (2009) 247-256
21. Järvinen R., Kaasinen E., Sankila A., and Rintala E. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mytomicin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol 56 (2009) 260-265
22. Sylvester RJ, Brausi MA, Hoelti W, et al. Long-term efficacy results of EORTC GU Group study 30911 comparing epirubicin, bacillus Calmette-Guerin (BCG), and BCG plus isoniazid in patients with intermediate and high risk stage TaT1 papillary carcinoma of the bladder. Eur Urol Suppl 2008; 3:298. Abstract 907.
23. Pawinski A., Sylvester R., Kurth K.H., et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156 (1996) 1934-1940